tiprankstipranks
Prelude Therapeutics Announces CFO Transition and Interim Appointment
Company Announcements

Prelude Therapeutics Announces CFO Transition and Interim Appointment

Don't Miss our Black Friday Offers:

Prelude Therapeutics (PRLD) just unveiled an update.

Prelude Therapeutics Incorporated has announced a change in their financial leadership, with CFO Laurent Chardonnet stepping down. Although no longer CFO as of April 8, 2024, Chardonnet will continue to provide consulting services to the company until October 4, 2024. He will receive severance pay equivalent to nine months of his base salary, in addition to other benefits. Subsequently, Bryant D. Lim, previously Chief Legal Officer and Corporate Secretary, has been named the interim CFO while the company searches for a permanent replacement. Lim brings a wealth of legal and compliance experience from the biotechnology industry to his new dual role.

See more data about PRLD stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPrelude Therapeutics Shows Strong Q3 2024 Financial Results
TheFlyPrelude Therapeutics reports Q3 EPS (43c), consensus (47c)
TheFlyPrelude Therapeutics price target lowered to $1 from $3 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App